当前位置: X-MOL 学术Eur. J. Med. Chem. › 论文详情
From irreversible to reversible covalent inhibitors: Harnessing the andrographolide scaffold for anti-inflammatory action.
European Journal of Medicinal Chemistry ( IF 5.572 ) Pub Date : 2020-07-12 , DOI: 10.1016/j.ejmech.2020.112481
Quy T N Tran,Daniel W S Tan,W S Fred Wong,Christina L L Chai

Covalent drugs with prolonged actions often show superior potency, yet integrated strategies for optimizing their structural and electronic features are lacking. Herein, we present our effort directed towards understanding the contribution of chemical reactivity to biological potency to rationally design new covalent inhibitors based on the ent-ladane andrographolide scaffold for anti-inflammatory action. Specifically, a series of andrographolide derivatives comprising various Michael acceptors was developed and their thiol reactivity was assayed under various chemical and biological conditions. The cell-based SAR studies permitted the assessment of the inhibitor efficacy in more complex systems, which were often limited in traditional covalent drug development using isolated proteins or peptides. Our in vitro study identified enone 17 as the most promising candidate which demonstrated potent anti-inflammatory activity and superior safety profiles as compared to the lead compound andrographolide. Its reversibility following a Michael addition reaction with biological thiols resulted in more predictable pharmacological responses. In addition, 17 exhibited good in vivo efficacy at doses as low as 0.3 mg/kg when tested in LPS-induced acute lung injury model. Given a good balance of chemical reactivity and biological potency, enone 17 potentially offers a new therapeutic option based on natural product chemistry for the management of inflammatory conditions.



中文翻译:

从不可逆到可逆共价抑制剂:利用穿心莲内酯支架进行抗炎作用。

具有延长作用的共价药物通常显示出优越的功效,但是缺乏优化其结构和电子特征的综合策略。在此,我们提出我们引向理解化学反应的贡献生物效价合理设计基础上,新的共价抑制剂努力耳鼻喉科-ladane穿心莲内酯支架的抗炎作用。具体而言,开发了包含各种迈克尔受体的一系列穿心莲内酯衍生物,并在各种化学和生物学条件下测定了它们的硫醇反应性。基于细胞的SAR研究允许在更复杂的系统中评估抑制剂的功效,这在使用分离的蛋白质或肽进行的传统共价药物开发中通常受到限制。我们的体外研究确定烯酮17是最有前途的候选药物,与铅类穿心莲内酯相比,它具有强大的抗炎活性和优越的安全性。其与生物硫醇的迈克尔加成反应后的可逆性导致更可预测的药理反应。另外,当在LPS诱导的急性肺损伤模型中进行测试时,有17种药物在低至0.3 mg / kg的剂量下表现出良好的体内功效。鉴于化学反应性和生物效能之间的良好平衡,烯酮17潜在地提供了基于天然产物化学的新治疗选择,可用于治疗炎症。

更新日期:2020-07-23
全部期刊列表>>
2021新春特辑
SN Applied Sciences期刊征稿中
JCR Q1医学全学科
虚拟特刊
亚洲大洋洲地球科学
NPJ欢迎投稿
自然科研论文编辑
ERIS期刊投稿
欢迎阅读创刊号
自然职场,为您触达千万科研人才
spring&清华大学出版社
城市可持续发展前沿研究专辑
Springer 纳米技术权威期刊征稿
全球视野覆盖
施普林格·自然新
chemistry
物理学研究前沿热点精选期刊推荐
自然职位线上招聘会
欢迎报名注册2020量子在线大会
化学领域亟待解决的问题
材料学研究精选新
GIANT
ACS ES&T Engineering
ACS ES&T Water
屿渡论文,编辑服务
阿拉丁试剂right
上海中医药大学
南科大-连续三周2.26
西湖大学
化学所
北京大学
山东大学
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
南方科技大学
张凤娇
中国石油大学
天合科研
x-mol收录
试剂库存
down
wechat
bug